Duract, Wyeth-Ayerst Laboratories

Approval Status
Approved July 1997

Treatment for
acute pain

Neurology & Nervous System , Cancer & Oncology

Bromfenac was cleared for marketing by the FDA on July 15, 1997. This provides an alternative to opioids for the management of acute pain. Bromfenac provides fast relief of acute pain without the side effects of opioid analgesics.

Possible adverse side effects include abdominal pain, headache, nausea, and vomiting.

Bromfenac Drug Information

The Bromfenac drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top